| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
21,946 |
17,088 |
$1.19M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,572 |
2,201 |
$252K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,171 |
4,928 |
$241K |
| 95819 |
|
835 |
682 |
$167K |
| 95816 |
|
588 |
555 |
$131K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
371 |
158 |
$65K |
| 95886 |
|
545 |
394 |
$58K |
| 95912 |
|
332 |
243 |
$45K |
| 95923 |
|
486 |
360 |
$38K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
471 |
425 |
$34K |
| 64483 |
|
244 |
185 |
$31K |
| 76942 |
|
937 |
478 |
$21K |
| 99215 |
Prolong outpt/office vis |
1,024 |
657 |
$19K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
2,225 |
1,426 |
$15K |
| 64493 |
|
195 |
122 |
$10K |
| 95700 |
|
27 |
26 |
$9K |
| 64615 |
|
222 |
136 |
$9K |
| 64490 |
|
105 |
75 |
$9K |
| 20552 |
|
412 |
235 |
$7K |
| 99233 |
Prolong inpt eval add15 m |
193 |
71 |
$7K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
1,880 |
1,173 |
$7K |
| 95813 |
|
35 |
31 |
$6K |
| 64484 |
|
137 |
103 |
$6K |
| 64494 |
|
196 |
122 |
$5K |
| 77002 |
|
804 |
318 |
$5K |
| 62321 |
|
49 |
41 |
$5K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
836 |
499 |
$5K |
| 64491 |
|
105 |
75 |
$4K |
| 99223 |
Prolong inpt eval add15 m |
42 |
27 |
$3K |
| 99205 |
Prolong outpt/office vis |
23 |
17 |
$3K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
107 |
56 |
$2K |
| 97124 |
|
62 |
25 |
$2K |
| 99152 |
|
121 |
88 |
$2K |
| 20553 |
|
76 |
40 |
$1K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
180 |
92 |
$952.56 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
134 |
96 |
$719.35 |
| 80053 |
Comprehensive metabolic panel |
154 |
126 |
$437.51 |
| 82607 |
|
141 |
110 |
$349.41 |
| 98960 |
|
27 |
25 |
$345.28 |
| 36415 |
Collection of venous blood by venipuncture |
324 |
251 |
$342.90 |
| 20611 |
|
18 |
12 |
$341.65 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
51 |
36 |
$247.31 |
| J3490 |
Unclassified drugs |
57 |
42 |
$217.94 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
171 |
91 |
$70.51 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
540 |
369 |
$43.40 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
1,785 |
897 |
$37.90 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
13 |
13 |
$9.86 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
48 |
25 |
$0.28 |
| 1160F |
|
2,131 |
1,833 |
$0.00 |
| 3288F |
|
126 |
101 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
148 |
106 |
$0.00 |
| 95951 |
|
52 |
14 |
$0.00 |
| 1124F |
|
98 |
74 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
160 |
119 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
124 |
91 |
$0.00 |
| G9584 |
Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy |
61 |
43 |
$0.00 |
| 93272 |
|
15 |
13 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
12 |
12 |
$0.00 |
| 82728 |
|
18 |
13 |
$0.00 |
| 85027 |
|
26 |
26 |
$0.00 |
| 1036F |
|
45 |
33 |
$0.00 |
| 2010F |
|
371 |
278 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
16 |
12 |
$0.00 |